These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24217767)

  • 1. MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
    Gao X; Shen K; Wang C; Ling J; Wang H; Fang Y; Shi Y; Hou Y; Qin J; Sun Y; Qin X
    Acta Biochim Biophys Sin (Shanghai); 2014 Jan; 46(1):72-5. PubMed ID: 24217767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
    Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
    Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
    Zheng S; Jia J; Pan YL; Tao DY; Lu HS
    Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
    Angelini S; Pantaleo MA; Ravegnini G; Zenesini C; Cavrini G; Nannini M; Fumagalli E; Palassini E; Saponara M; Di Battista M; Casali PG; Hrelia P; Cantelli-Forti G; Biasco G
    Pharmacol Res; 2013 Feb; 68(1):1-6. PubMed ID: 23127916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
    Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
    Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.
    Kou Y; Yang R; Wang Q
    J Biosci; 2018 Dec; 43(5):1015-1023. PubMed ID: 30541960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of imatinib for treatment of metastatic GIST.
    Patel S
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [GIST refractory to imatinib treatment].
    Onozawa Y; Terashima M
    Gan To Kagaku Ryoho; 2011 May; 38(5):738-43. PubMed ID: 21566433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.
    Shi Y; Gao X; Hu Q; Li X; Xu J; Lu S; Liu Y; Xu C; Jiang D; Lin J; Xue A; Tan Y; Shen K; Hou Y
    Lab Invest; 2016 Jun; 96(6):652-60. PubMed ID: 26950487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor.
    Agulnik M; Giel JL
    Am J Clin Oncol; 2014 Aug; 37(4):417-22. PubMed ID: 22772433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report.
    Rediti M; Pellegrini E; Molinara E; Cerullo C; Fonte C; Lunghi A; Iori A; Neri B
    Anticancer Res; 2014 Feb; 34(2):905-7. PubMed ID: 24511030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.
    Quattrone A; Wozniak A; Dewaele B; Floris G; Vanspauwen V; Van Looy T; Schöffski P; Rutkowski P; Sciot R; Debiec-Rychter M
    Mod Pathol; 2014 Nov; 27(11):1510-20. PubMed ID: 24743220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
    López RL; del Muro XG
    Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of gastrointestinal stromal tumor: the imatinib era and beyond.
    Parikh PM; Gupta S
    Indian J Cancer; 2013; 50(1):31-40. PubMed ID: 23713042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
    Pisters PW; Colombo C
    J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
    Ogata K; Mochiki E; Ojima H; Haga N; Fukuchi M; Aihara R; Ando H; Uchida N; Toyomasu Y; Suzuki M; Kimura A; Kogure N; Yokobori T; Ohno T; Kuwano H
    J Surg Oncol; 2014 Dec; 110(8):942-6. PubMed ID: 25164620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.